Status:

ACTIVE_NOT_RECRUITING

Obesity Group Visits. A Novel Way to Approach the Obesity Epidemic in an Inner-City Setting

Lead Sponsor:

Charles Drew University of Medicine and Science

Conditions:

Obesity

Eligibility:

All Genders

18-90 years

Phase:

NA

Brief Summary

The purpose of this study has two aims: Aim 1: To compare a medical group visit model versus a dietitian-let model (shared composite group visit approach vs individualized dietitian-led approach) to p...

Detailed Description

After being informed about the study and potential risks, all study participants giving written informed consent will be screened to determine eligibility for study entry. At week 0, study participant...

Eligibility Criteria

Inclusion

  • Inclusion
  • Age ≥ 18
  • BMI ≥ 30 kg/m2
  • Male, Female, LGBT
  • Any ethnicity
  • Interested in weight loss and be open to being randomized in either a medical group visit arm or dietitian-led arm (willingly agree to sign consent form)
  • Currently within or be eligible to receive care at LAC-DHS and be empaneled to have a primary care provider (PCP) who can adjust their medicines including anti-hypertensive and diabetic medications if needed.
  • If had stopped taking weight loss medication (orlistat, lorcaserin, and phentermine/topiramate-ER, phenetermine, diethylpropion, phendimetrazine and benzphetamine) for at least 2 months prior enrollment
  • If had stopped taking supplements advertised to increase weight loss at least 3 months prior enrollment
  • Females \>50 years of age and Males \>40 years of age meet inclusion criteria to participate in the sub-study that involves getting a Coronary Artery Calcium (CAC) scan done at the Lundquist Institute.
  • Exclusion Criteria:
  • Age \<18
  • BMI\< 30 kg/m2
  • Unwilling to sing consent form
  • Currently participating in another obesity treatment program
  • Currently on a weight loss medication (orlistat, lorcaserin, and phentermine/topiramate-ER, phenetermine, diethylpropion, phendimetrazine and benzphetamine)
  • Currently on metformin or topiramate primarily prescribed for weight loss
  • Currently pregnant
  • Ineligible to receive care at LAC-DHS
  • Those with mental illness, substance abuse issues as well as other illnesses who are unable to follow directions related to the study or becomes disruptive to the overall group
  • Patients who have had bariatric surgery less than a year from time of enrollment
  • Females \<50 years of age and Males \<40 years of age are not eligible to participate in the sub-study that involves getting a Coronary Artery Calcium (CAC) scan done at the Lundquist Institute.

Exclusion

    Key Trial Info

    Start Date :

    February 3 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 28 2025

    Estimated Enrollment :

    1000 Patients enrolled

    Trial Details

    Trial ID

    NCT04725058

    Start Date

    February 3 2020

    End Date

    December 28 2025

    Last Update

    April 15 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Charles R. Drew University of Medicine and Science

    Los Angeles, California, United States, 90059